As of June 20, 2025, H-Cyte Inc (HCYT) reports a Gross Margin of 74.07%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of H-Cyte Inc's Gross Margin
Over recent years, H-Cyte Inc's Gross Margin has shown significant volatility. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2022-12-31 | 74.07% |
| 2021-12-31 | 56.27% |
| 2020-12-31 | 64.34% |
| 2019-12-31 | 75.41% |
| 2018-12-31 | 69.98% |
This slight upward trend highlights how H-Cyte Inc manages its operational efficiency and pricing power over time.
Comparing H-Cyte Inc's Gross Margin to Peers
To better understand H-Cyte Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| H-Cyte Inc (HCYT) | 74.07% |
| PZ Wind Down Inc (PZRXQ) | 7775.20% |
| Multicell Technologies Inc (MCET) | 7775.20% |
| Rasna Therapeutics Inc (RASP) | 7775.20% |
| Viewbix Inc (VBIX) | 7775.20% |
| Alseres Pharmaceuticals Inc (ALSE) | 7775.20% |
Compared to its competitors, H-Cyte Inc's Gross Margin is about average compared to peers, indicating industry-standard operational efficiency.